Fennec Pharmaceuticals Inc (FENC)

Etorro trading 970x250

About Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina. Address: 68 TW Alexander Drive, Research Triangle Park, NC, United States, 27709

Fennec Pharmaceuticals Inc News and around…

Latest news about Fennec Pharmaceuticals Inc (FENC) common stock and company :

Fennec Pharmaceuticals Inc. (NASDAQ: FENC) Investor Notice: Investigation over Possible Violations of Securities Laws
16 Dec, 2021 FinancialContent

San Diego, CA -- (SBWIRE) -- 12/16/2021 -- An investigation for investors in Fennec Pharmaceuticals Inc. (NASDAQ: FENC) shares over potential securities laws violations by Fennec Pharmaceuticals Inc. was announced.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fennec Pharmaceuticals Inc. - FENC
15 Dec, 2021 Yahoo! Finance

NEW YORK, NY / ACCESSWIRE / December 14, 2021 / Pomerantz LLP is investigating claims on behalf of investors of Fennec Pharmaceuticals Inc. ("Fennec" or the "Company") (NASDAQ:FENC).

RTP drugmaker suffers another regulatory setback
01 Dec, 2021 Yahoo! Finance

A pharmaceutical company in Research Triangle Park is facing another regulatory setback as it tries to move its drug to the market.

Fennec (FENC) Gets CRL From FDA for Pedmark, Stock Down
30 Nov, 2021 Yahoo! Finance

Fennec (FENC) suffers a setback again with a CRL for its new drug application (NDA) for Pedmark. Shares are down in pre-market trading.

FENC – Fennec Pharmaceuticals Inc. Investors Who Have Lost More Than $25,000 Are Encouraged To Contact Kehoe Law Firm, P.C. – Securities Class Action Investigation
30 Nov, 2021 Yahoo! Finance

PHILADELPHIA, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating whether Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) (NASDAQ: FENC) violated federal securities laws or engaged in other unlawful business practices. FENNEC INVESTORS WITH FINANCIAL LOSSES GREATER THAN $25,000 ARE ENCOURAGED TO COMPLETE KEHOE LAW FIRM’S SECURITIES CLASS ACTION QUESTIONNAIRE. On November 29, 2021, Fennec reported that “. . . it expects the U.S. Food and Drug Administration will not ac

Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors
30 Nov, 2021 Yahoo! Finance

RESEARCH TRIANGLE PARK, N.C., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that it received a Complete Response Letter (CRL) on November 29, 2021 from the U.S. Food and Drug Administration (FDA), after the PDUFA target action date of November 27, 2021, regarding its New Drug Application (NDA) for PEDMARK™ (a unique formulation of sodium thiosulfate), for intravenous administration for the prevention of ototoxicity associated w

When Will Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Breakeven?
30 Nov, 2021 Yahoo! Finance

Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) is possibly approaching a major achievement in its business, so we would...

50 Biggest Movers From Yesterday
30 Nov, 2021 FinancialContent

Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares surged 121.7% to close at $88.24 on Monday after the company announced ...

Mid-Afternoon Market Update: Dow Jumps 300 Points; Krystal Biotech Shares Spike Higher
29 Nov, 2021 FinancialContent

Toward the end of trading Monday, the Dow traded up 0.87% to 35,204.42 while the NASDAQ climbed 1.96% to 15,795.08. The S&P also ...

Stocks Rise as "Fear Gauge" Cools Off
29 Nov, 2021 FinancialContent

The Dow Jones Industrial Average and Nasdaq Composite are both up triple digits midday, paring some of their losses from Friday's massive selloff.

Mid-Day Market Update: Crude Oil Rises 4%; Fennec Pharmaceuticals Shares Slide
29 Nov, 2021 FinancialContent

Midway through trading Monday, the Dow traded up 0.30% to 35,005.10 while the NASDAQ climbed 1.39% to 15,707.48. The S&P also rose, ...

33 Stocks Moving In Monday's Mid-Day Session
29 Nov, 2021 FinancialContent

Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares jumped 116.4% to $86.13 after the company announced positive topline results ...

Mid-Morning Market Update: Markets Open Higher; Li Auto Sales Top Views
29 Nov, 2021 FinancialContent

Following the market opening Monday, the Dow traded up 0.22% to 34,977.01 while the NASDAQ climbed 1.53% to 15,727.94. The S&P also ...

Fennec Pharma Stock Plunges On Expected FDA CRL For Pedmark For Chemo-Induced Hearing Issues
29 Nov, 2021 FinancialContent

Fennec Pharmaceuticals Inc(NASDAQ: FENC) said itexpects to receive a Complete Response Letter(CRL) from the FDA ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
29 Nov, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips I hope you got your rest out over the holiday weekend because we're starting off Monday with the biggest pre-market stock movers! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

Fennec Pharmaceuticals Expects FDA Rejection for New Drug
29 Nov, 2021 Yahoo! Finance

By Sam Boughedda

Fennec Pharmaceuticals Expects to Receive Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors
29 Nov, 2021 Yahoo! Finance

FDA Pre-Approval Inspection Identified Deficiencies with the Facility of the Drug Product Manufacturer, Which Require Resolution Prior to PEDMARK ApprovalRESEARCH TRIANGLE PARK, N.C., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that it expects to receive a Complete Response Letter (CRL) after the PDUFA target action date of November 27, 2021 from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (

The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
21 Nov, 2021 FinancialContent

Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting season and ahead of the holiday week.

The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
21 Nov, 2021 FinancialContent

Biotech stocks showed a lack of direction in the week endingNov. 19 before finishing modestly higher. Stocks did not have much ...

The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
10 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To ...

Fennec Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business Update
10 Nov, 2021 Yahoo! Finance

~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~ ~ If Approved by the FDA, PEDMARK™ Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ~ Company Has Approximately $24 Million in Cash and Cash Equivalents ~ RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique for

Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
02 Nov, 2021 FinancialContent

The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for ...

4 Breakout Stocks for Impressive Returns
05 Oct, 2021 Yahoo! Finance

SB, VTSI, FENC and APYX qualified the screen for breakout stocks for today.

The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
29 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
09 Sep, 2021 FinancialContent
Fennec Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update
10 Aug, 2021 FinancialContent
Is Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Popular Amongst Institutions?
02 Aug, 2021 Yahoo! Finance

If you want to know who really controls Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ), then you'll have to look at the...

Fennec Announces Results of Annual Meeting
29 Jun, 2021 FinancialContent
Fennec Pharmaceuticals Announces Amendment to Increase Existing Senior Debt Facility
24 Jun, 2021 FinancialContent
The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal
22 Jun, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Fennec Pharmaceuticals Inc (FENC) is a NASDAQ Common Stock listed in , ,

970x250